Bayer places new bonds with a volume of 5.75 billion U.S. dollars

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Leverkusen, November 17, 2023 – On Thursday, the Bayer Group successfully placed bonds with a volume of 5.75 billion U.S. dollars, which will be issued by its subsidiary Bayer US Finance LLC, St. Louis, United States, and guaranteed by Bayer AG. The expected ratings of the bonds are Baa2 by Moody’s, BBB by S&P and BBB+ by Fitch. The placement comprises five tranches with maturities between 3 and 30 years and exclusively targets institutional investors. All tranches were multiple times oversubscribed. Bayer intends to use the net proceeds for general corporate purposes. Closing of the transaction is expected on November 21, 2023.

The bonds have fixed interest rates of 6.125 percent p. a. (volume of 1.0 billion U.S. dollars, maturing in 2026), 6.250 percent p. a. (volume of 1.0 billion U.S. dollars, maturing in 2029), 6.375 percent p. a. (volume of 1.25 billion U.S. dollars, maturing in 2030), 6.500 percent p.a. (volume of 1.75 billion U.S. dollars, maturing in 2033) and 6.875 percent p. a. (volume of 0.75 billion U.S. dollars, maturing in 2053).

Citi, J.P. Morgan, SMBC and Wells Fargo Securities led the transaction as active bookrunners.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Important Notice
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities referred to herein in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction.

The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. state security laws and may not be offered or sold in the United States or to, or for the benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act.